Bellevue Group AG Has $1.55 Million Stake in Dr. Reddy's Laboratories Limited (NYSE:RDY)

Bellevue Group AG raised its holdings in Dr. Reddy's Laboratories Limited (NYSE:RDY - Free Report) by 375.4% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 97,900 shares of the company's stock after acquiring an additional 77,305 shares during the quarter. Bellevue Group AG's holdings in Dr. Reddy's Laboratories were worth $1,546,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently made changes to their positions in RDY. Robeco Institutional Asset Management B.V. boosted its holdings in Dr. Reddy's Laboratories by 453.8% during the fourth quarter. Robeco Institutional Asset Management B.V. now owns 11,438,908 shares of the company's stock worth $180,620,000 after buying an additional 9,373,412 shares in the last quarter. Renaissance Technologies LLC raised its position in shares of Dr. Reddy's Laboratories by 382.9% during the fourth quarter. Renaissance Technologies LLC now owns 9,418,428 shares of the company's stock worth $148,717,000 after purchasing an additional 7,467,979 shares during the period. Aikya Investment Management Ltd lifted its holdings in shares of Dr. Reddy's Laboratories by 416.1% during the fourth quarter. Aikya Investment Management Ltd now owns 5,610,503 shares of the company's stock valued at $88,590,000 after purchasing an additional 4,523,303 shares during the last quarter. Dimensional Fund Advisors LP lifted its holdings in shares of Dr. Reddy's Laboratories by 405.9% during the fourth quarter. Dimensional Fund Advisors LP now owns 5,361,013 shares of the company's stock valued at $84,643,000 after purchasing an additional 4,301,212 shares during the last quarter. Finally, Vanguard Group Inc. increased its stake in Dr. Reddy's Laboratories by 397.2% in the 4th quarter. Vanguard Group Inc. now owns 4,896,185 shares of the company's stock worth $77,311,000 after purchasing an additional 3,911,404 shares in the last quarter. Institutional investors own 3.85% of the company's stock.

Dr. Reddy's Laboratories Stock Performance

RDY stock remained flat at $13.51 during mid-day trading on Wednesday. 1,843,301 shares of the company's stock were exchanged, compared to its average volume of 1,483,994. The stock has a 50-day moving average of $13.27 and a two-hundred day moving average of $14.12. The stock has a market capitalization of $11.28 billion, a P/E ratio of 21.51 and a beta of 0.33. The company has a debt-to-equity ratio of 0.02, a quick ratio of 1.38 and a current ratio of 1.92. Dr. Reddy's Laboratories Limited has a 52 week low of $12.26 and a 52 week high of $16.89.

About Dr. Reddy's Laboratories

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.